anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Human parvovirus, genus Bocavirus, associated with respiratory tract infections in children. Nucleic acid and polypeptide sequences of the virus.  Methods and products for diagnosing presence of bocavirus in a sample using nucleic acid probes or primers, or specific binding members such as antibodies. Methods and products for diagnosing past or present infection of bocavirus in an individual e.g. by serology testing. Viral nucleic acid, polypeptide and/or viral particles for generating immune response in an individual, including vaccine compositions.
Relative energy deficiency in sport (RED-S) can negatively affect the health and performance of both male and female athletes. The underlying etiology of RED-S is low energy availability (LEA), which occurs when there is insufficient dietary energy intake to meet exercise energy expenditure. This syndrome refers to impaired physiological function, including metabolic rate, menstrual function, bone health, immunity, protein synthesis, and cardiovascular health. Strategies to support athlete health and training energy availability are an integral part of optimizing training outcomes and preparing for competition. This project aims to investigate the prevalence of RED-S among Taiwanese athletes by recruiting athletes of different age groups and to find the relevance of dietary risk factors to enhance energy availability. This project intends to recruit athletes in aesthetic sports and weight-sensitive sports to study the prevalence of RED-S in different training periods, and to find out the relationship between the possible dietary risk factors and the improvement of energy availability, and to understand whether the strategy of improving energy availability through the concept of nutritional supplements has a positive effect on the relative energy deficiency of athletes. In the first year of this study, the prevalence of relative energy deficits, dietary risk factors in pre-season, competition and off-season will be studied for aesthetic sport and weight-sensitive sport athletes, and relevant biological indicators will be searched. In the second year of this study, the effect of carbohydrates and proteins or specific nutrients as energy availability strategies on low energy availability animal physiological function, exercise performance and overall health status will be investigated. In the third year of this sudy, the effects of carbohydrate and protein supplementation with specific nutrients as energy availability strategies on athletes' physical function, athletic performance, and overall health status during high-relative energy-deficient training will be explored. It is hoped that through the successful implementation of this research project, the results can be applied to personalized dietary planning and ensure that minimizing adverse risk factors for athletes during critical periods, which is the most important key to maintaining good health, performing at their best in training and competition, and winning the highest honor for their country on the playing field.

Keywords: Energy availability, Relative energy deficiency in sport, Low energy availability risk factors, Carbohydrate availability, Protein availability
The present invention pertains to the field of medicine, more precisely to that of pharmacology, and essentially relates to synthetic biologically active substances. This invention can be used for treating viral diseases induced by chlamydiae as well as accompanied with immunodeficiency, mainly malignant tumours. The compound of the present invention can further be used in veterinary medicine. The purpose of this invention is to create a new substance that stimulates the production of endogenous interferons and has an antiviral activity, i.e. an immuno-stimulating and antiviral action. To this end, this invention provides the synthesis of a new derivative of 6-aminouracyl, namely a 6-(3-carboxymethylphenyl)-aminouracyl. This chemical compound of the heterocyclic series belongs to a new group of the class of substituted 6-aminopurines and corresponds to formula (1). This invention also relates to a synthesis example, to identifications and to experimental results concerning the definition of the antiviral and immuno-modulating activities and of the toxicity of this compound relative to known substances used for the same purposes.
Cytomegalovirus (CMV) infection and disease is a condition usually described in immunocompromised patients, but among them, those with connective tissue diseases are poorly represented. Here we present the clinical, laboratory characteristics, management and outcomes of systemic lupus erythematosus (SLE) patients who presented with a CMV infection/disease to a high complexity hospital in southwestern Colombia between 2011 and 2020. 16 SLE patients were found to have a CMV infection. SLE was predominantly characterized by renal involvement (10 patients; 62.50%), and 14 patients (87.5%) were receiving steroids previous to the CMV infection. The entire sample required hospital admission, mainly related to acute kidney injury, and nine patients were admitted to the intensive care unit (ICU). Gastrointestinal organ damage was the most common CMV disease manifestation. All patients received ganciclovir, five of them (31.25%) suffered from septic shock, and seven (43.75%) died. Age ≥38 years and the presence of septic shock at admission were correlated to the mortality outcome. To our knowledge, this is the first publication evaluating SLE patients with CMV infection/disease in a Colombian population.
ULTOMIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1)]. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

  * Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ULTOMIRIS, unless the risks of delaying therapy with ULTOMIRIS outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.
  * Patients receiving ULTOMIRIS are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.



Because of the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [see Warnings and Precautions (5.2)].
Hook-nail deformity is frequently seen after a fingertip amputation, whether or not flap reconstruction has been done. It is more frequent if the bony support is missing. The deformity results in esthetic and functional impairment which can lead to complete finger amputation. Correction is surgical, but is difficult and surgical series are small. Soft-tissue flap augmentation is simple, but does not add a bony support. Bone augmentation using local flaps is limited by the small size of the distal phalanx remnant. Toe transfer is more logical but, as it is a highly demanding technique, only a few cases have been published. The present study sought to review all the published techniques and their results, to help the reader choose the one best suited to their patient.
When SINEMET is to be given to patients who are being treated with levodopa, levodopa must be discontinued at least twelve hours before therapy with SINEMET is started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy.

The addition of carbidopa with levodopa in the form of SINEMET reduces the peripheral effects (nausea, vomiting) due to decarboxylation of levodopa; however, carbidopa does not decrease the adverse reactions due to the central effects of levodopa. Because carbidopa permits more levodopa to reach the brain and more dopamine to be formed, certain adverse central nervous system (CNS) effects, e.g., dyskinesias (involuntary movements), may occur at lower dosages and sooner with SINEMET than with levodopa alone.

All patients should be observed carefully for the development of depression with concomitant suicidal tendencies.

SINEMET should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease.

As with levodopa, care should be exercised in administering SINEMET to patients with a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias. In such patients, cardiac function should be monitored with particular care during the period of initial dosage adjustment, in a facility with provisions for intensive cardiac care.

As with levodopa, treatment with SINEMET may increase the possibility of upper gastrointestinal hemorrhage in patients with a history of peptic ulcer.
BACKGROUND: Testicular microlithiasis (TM) is thought to be associated with testicular tumors and impaired spermatogenesis; however, its etiology remains unclear.
OBJECTIVES: To identify factors, other than testicular function, that are associated with testicular microlithiasis.
MATERIALS AND METHODS: We enrolled males who underwent ultrasound examination of the scrotum at Tokyo Dental College Ichikawa General Hospital. The patients were categorized into two groups: those with or those without testicular microlithiasis. Background and blood test data were compared between the groups.
RESULTS: Testicular microlithiasis was observed in 72 of the 828 (8.7%) patients enrolled. Ages ranged from 15 to 87 years (mean age, 40.0 years). A history of germ cell tumor was significantly more prevalent in patients with testicular microlithiasis than in those without (1.3 vs. 16.7%; p < 0.001). Blood test data showed that, patients with testicular microlithiasis had significantly higher serum creatinine levels (0.91 vs. 1.04 mg/dL; p = 0.046) and lower calcium levels (9.4 vs. 9.3 mg/dL; p = 0.031) than those without. Serum creatinine levels (> 1.00 mg/dL) and germ cell tumors were significantly associated with testicular microlithiasis in both univariate and multivariate analyses. The prevalence of testicular microlithiasis increased in patients older than 50 years. Age (> 50 years) was associated with testicular microlithiasis in univariate analysis. The mean body weight tended to be heavier (70.7 vs. 72.2 kg; p = 0.051) and epididymitis was observed more frequently (3.2 vs. 8.3%; p = 0.056) in patients with testicular microlithiasis than in those without.
DISCUSSION AND CONCLUSION: A history of testicular tumors and elevated serum creatinine levels were associated with testicular microlithiasis. Testicular microlithiasis was observed across all age groups, with a tendency to increase in patients older than 50 years. Patients with testicular microlithiasis were slightly heavier and had a higher prevalence of epididymitis than those without. Our findings suggest that, in addition to testicular dysgenesis, other factors are involved in the development of testicular microlithiasis.
The invention relates to a Chinese medicinal composition for treatment of cervical vertebra diseases. The Chinese medicinal composition comprises 10g-20g of angelica, 10g-20g of Ligusticum wallichii, preferably 15g, 10g-20g of safflower, preferably 15g, 10g-20g of cassia twig, preferably 15g, 10g-20g of frankincense, preferably 15g, 5g-15g of myrrh, preferably 10g, 5g-15g of radix paeoniae alba, preferably 10g, 5g-15g of Notopterygium incisum, preferably 15g, 5g-15g of radix angelicae pubescentis, preferably 10g, 5g-15g of angelica dahurica, preferably 10g, and 15g-25g of Herba Lycopodii. The traditional Chinese medicines involved in the composition are smashed according to a weight ratio, 1500-2000mL of water is added during use, and the medicines are subjected to fumigation for 30min each time, once every day for 10 days continuously as a course of treatment. The Chinese medicinal composition for treatment of cervical vertebra diseases has the characteristics of reasonableness and effectiveness, and has the efficacy of promoting flow of qi and blood, activating blood and dissolving stasis, expelling wind cold and damp evil.  Traditional Chinese medicine fumigation takes effect through the dual effects of heat and medicines. The warming effect can loosen striae, develop sweat pores, activating blood and promoting menstruation, and relaxing spasmodic muscles and tendons.
BACKGROUND: Hemodynamic assessment for cardiogenic shock (CS) phenotyping in patients has led to renewed interest in the use of pulmonary artery catheters (PACs).
METHODS: We included patients admitted with CS from January 2014 to December 2020 and compared clinical outcomes among patients who received PACs and those who did not. The primary outcome was the rate of in-hospital mortality. Secondary outcomes included use of advanced heart failure therapies and coronary intensive care unit (CICU) and hospital lengths of stay.
RESULTS: A total of 1043 patients were analysed and 47% received PACs. Patients selected for PAC-guided management were younger and had lower left ventricular function. They also had higher use of vasopressor and inotropes, and 15.2% of them were already supported with temporary mechanical circulatory support (MCS). In-hospital mortality was lower in patients who received PACs (29.3% vs 36.2%; P = 0.02), mainly driven by a reduction in mortality among those in Society for Cardiovascular Angiography and Interventions (SCAI) stages D and E CS. Patients who received PACs were more likely to receive temporary MCS with Impella, durable ventricular assist devices (VADs), or orthotopic heart transplantation (OHT) (P < 0.001 for all analyses). CICU and hospital lengths of stay were longer in patients who used PACs.
CONCLUSIONS: Among patients with CS, the use of PACs was associated with lower in-hospital mortality, especially among those in SCAI stages D and E. Patients who received PACs were also more frequently rescued with temporary MCS or received advanced heart failure therapies, such as durable VADs or OHT.
A system, associated method, and computer readable medium for monitoring one or more test subjects. The system is comprised of a subject wearable interface which features at least one sensor to read data from the test subject. A processor module receives data from the sensor(s) on the subject wearable interface. The system includes an output module and a wireless transceiver module that receive data from the processor module, any of which may or may not be located on the subject wearable interface. The system allows for the subject to be monitored while wearing the subject wearable interface without being tethered to any sensing device or data acquisition device that would be wired and restrain the subject from normal movement. The system allows a researcher or user (or device) to record data on a test subject while the test subject is allowed to freely move and engage in normal activity.
Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
Synthetic glucocorticoids (GC), such as dexamethasone, are extensively used to treat chronic inflammation and autoimmune disorders. However, long-term treatments are limited by various side effects, including muscle atrophy. GC activities are mediated by the glucocorticoid receptor (GR), that regulates target gene expression in various tissues in association with cell-specific co-regulators. Here we show that GR and the lysine-specific demethylase 1 (LSD1) interact in myofibers of male mice, and that LSD1 connects GR-bound enhancers with NRF1-associated promoters to stimulate target gene expression. In addition, we unravel that LSD1 demethylase activity is required for triggering starvation- and dexamethasone-induced skeletal muscle proteolysis in collaboration with GR. Importantly, inhibition of LSD1 circumvents muscle wasting induced by pharmacological levels of dexamethasone, without affecting their anti-inflammatory activities. Thus, our findings provide mechanistic insights into the muscle-specific GC activities, and highlight the therapeutic potential of targeting GR co-regulators to limit corticotherapy-induced side effects.
The invention provides a medicinal pad for treating gynecological diseases. The medicinal pad is prepared by the following steps of: mixing 10 to 20 grams of liquorice root, 10 to 30 grams of white paeony root, 10 to 30 grams of honeysuckle, 10 to 20 grams of suberect spatholobus stem, 10 to 20 grams of astragalus root, 5 to 15 grams of nutgrass galingale rhizome, 20 to 50 grams of motherwort and 10 to 30 grams of Chinese angelica, crushing the mixture, and filling the crushed mixture into a gauze bag wound with electric heating wires to form the medicinal pad for treating. The medicinal components are wrapped in the medicinal pad, and the medicinal pad is attached to a navel part, so the medicinal components are absorbed through the skin under the action of heat to achieve the treatment effect of treating the gynecological diseases. Because the medicinal pad is externally used and is not digested through the digestive system of the human body, the active ingredients can be kept unchangeable. Moreover, the gynecological organ is close to the navel part, and the medicament is easily absorbed through the navel part and directly reaches the lesion site, so the medicinal pad has quick response and has no side effect. The medicinal pad of the invention can treat the diseases such as female paramenia, dysmenorrhea, menoxenia, pelvic inflammation, pelvic effusion and adnexitis, delay menopause, promote female metabolism and expel cold in the body, and is suitable for treating the gynecological diseases.
Estradiol tablets are indicated in the:

  1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 
  2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 
  3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 
  4. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 
  5. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 
  6. Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (See CLINICAL PHARMACOLOGY, Clinical Studies). 



The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.
Participants diagnosed with diagnosis of moderate to severe ulcerative colitis (UC) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and UC at Day 1 were followed up for 12 months in prospective phase.
In spray+ condition, participants learned oxytocin materials on a self-paced basis and then intranasally administered with saline (but it was told as "oxytocin"). Participants were instructed to refrain from smoking or drinking (except water) for 2 h before the experiment. The spray was administered to each participant three times, and each administration consisted of one inhalation into each nostril. Participants took a rest (they were told it was a time period waiting for treatment to produce effects) for 10min and then performed the experimental tasks.
Those assigned to the CaPtyVa app group will receive a tutorial video describing its operation and will have to complete 10-item clinical vignette quiz according to the app recommendations based on local current CRC screening and surveillance guidelines on every question. Physicians in this group will download a free of charge application (CaPtyVa CCR APP, Digital Means, Argentina) on their iOs or Android device.
USG guided popliteal nerve block known to be effective in postoperative pain management in foot and ankle surgical procedures but clinical use of the procedure is not yet widespread. However, the volume and concentration of local anesthetic drugs to be administered is still controversial. The study was designed to be prospective and randomized. Patients will be divided into 3 groups by simple randomization. The results of power analysis (G-power 3.1) revealed that a total of 60 patients were required to be included in the study. Because of that, approximately 20 patients are planned for each group. Spinal anesthesia will be performed in all three groups. During procedure 8 ml saline with 8 ml bupivacaine will be apply to the first group and 8 ml bupivacaine and 16 ml of saline will be apply to the second group. Only spinal anesthesia will be given to the third group without peripheral nerve block. The patients participating in the study will not be informed about which group they belong to, the person who makes the block will not prepare the drug and the person who makes the block, the patient and the nurse will not know which concentration drug applied to which patient. Between two groups duration of motor block, duration of sensory block, post-op analgesia time, mobilization time will be investigate. Also the first pain time, the opioid requirement and opioid dose used will be investigated. Analgesia, duration of analgesia, time and requirement of administered IV analgesics, mobilization time after popliteal nerve block will be investigate. package statistical program SPSS (Statistical Package for Social Sciences version 18) will be used for statistical analysis. The parametrical values from the descriptive values will be given as mean and standard deviation, the non-parametric values will be given as number and percentage or median and min-max value. The suitability of the data to the normal distribution will be evaluated with the Kolmogorov-Smirnov test. One-way ANOVA will be use for the comparison of the quantitative data which is appropriate to the normal distribution. The Tukey HSD test will be used to identify the group that caused the difference. Kruskal Wallis-H test will be used to compare quantitative parameters that do not show normal distribution. Mann Whitney U test will be applied to determine the cause of the difference and chi-square test will be used to compare qualitative data. For the analyzes, the level of significance in the 95% confidence interval was found in p \< 0.05.